GSS Investor Presentation - Proposed Merger with MAP

Key points

• Proposed merger aims to create a scaled ASX-listed diagnostics group
• Combined entity to have approximately $30 million FY26 revenue
• Transaction funded entirely in scrip with GSS shareholders holding 33% of merged group

Full summary

Genetic Signatures Limited (ASX:GSS) has announced a proposed merger with Microba Life Sciences Limited (ASX:MAP), aiming to create a scaled ASX-listed diagnostics group. The combined entity is expected to generate approximately $30 million in FY26 revenue, with Microba's metagenomic testing complementing Genetic Signatures' syndromic PCR. The transaction will be funded entirely in scrip, with Genetic Signatures shareholders holding approximately 33% of the merged group. The merger is expected to provide a materially wider route to market, enhanced scale, and financial benefits, including approximately $30 million in combined cash and term deposits.

Guidance

Combined FY26 revenue of approximately $30 million, combined cash and term deposits of approximately $30 million

Outlook

The merger is expected to create a scaled ASX-listed leader in gastrointestinal and infectious disease diagnostics, with a materially wider route to market and enhanced scale.